ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Brief description of study

ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study will compare event- free survival, functional/behavioral outcomes and quality of life measures for patients treated with CV versus selumetinib.

Clinical Study Identifier: s20-00079 Identifier: NCT04166409

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.